Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick C Ma

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|July 30, 2005
Role of c-MET in upper aerodigestive malignancies--from biology to novel therapiesSascha Dietrich, Radha Uppalapati, Tanguy Y Seiwert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycinPatrick C Ma, Erik Schaefer, James G Christensen, et al.
Neoplasia (New York, N.Y.)|November 2, 2017
Nothing But NET: A Review of Neuroendocrine Tumors and CarcinomasBryan Oronsky, Patrick C Ma, Daniel Morgensztern, et al.
Case Reports in Oncology|November 26, 2019
The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and ResistanceAlbina Kibirova, Malcolm D Mattes, Matthew Smolkin, et al.
Translational Lung Cancer Research|November 19, 2019
Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challengeZeeshan Ahmad, Qasim Stanazai, Staphanie Wright, et al.
Case Reports in Oncology|December 28, 2017
Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the PleuraJames T Boothe, G Thomas Budd, Matthew B Smolkin, et al.
Expert Opinion on Therapeutic Targets|May 4, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapiesMatthew Lee, Prantesh Jain, Feng Wang, et al.
Journal of Medical Imaging and Radiation Oncology|September 4, 2020
Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancerChristina G Attia, Naomi Fei, Mohammed Almubarak, et al.
Cytokine & Growth Factor Reviews|December 26, 2001
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibitionGautam Maulik, Amol Shrikhande, Takashi Kijima, et al.
Anticancer Research|May 25, 2004
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancerAjit Bharti, Patrick C Ma, Gautam Maulik, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|July 30, 2005
Role of c-MET in upper aerodigestive malignancies--from biology to novel therapiesSascha Dietrich, Radha Uppalapati, Tanguy Y Seiwert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycinPatrick C Ma, Erik Schaefer, James G Christensen, et al.
Neoplasia (New York, N.Y.)|November 2, 2017
Nothing But NET: A Review of Neuroendocrine Tumors and CarcinomasBryan Oronsky, Patrick C Ma, Daniel Morgensztern, et al.
Case Reports in Oncology|November 26, 2019
The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and ResistanceAlbina Kibirova, Malcolm D Mattes, Matthew Smolkin, et al.
Translational Lung Cancer Research|November 19, 2019
Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challengeZeeshan Ahmad, Qasim Stanazai, Staphanie Wright, et al.
Case Reports in Oncology|December 28, 2017
Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the PleuraJames T Boothe, G Thomas Budd, Matthew B Smolkin, et al.
Expert Opinion on Therapeutic Targets|May 4, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapiesMatthew Lee, Prantesh Jain, Feng Wang, et al.
Journal of Medical Imaging and Radiation Oncology|September 4, 2020
Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancerChristina G Attia, Naomi Fei, Mohammed Almubarak, et al.
Cytokine & Growth Factor Reviews|December 26, 2001
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibitionGautam Maulik, Amol Shrikhande, Takashi Kijima, et al.
Anticancer Research|May 25, 2004
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancerAjit Bharti, Patrick C Ma, Gautam Maulik, et al.
Pageof 9